Marshall, Gerstein & Borun LLP

Partner

Mark H. Izraelewicz is a partner at Marshall, Gerstein & Borun LLP. He recently led CureVac’s U.S. litigation strategy in its high-profile mRNA patent dispute against Pfizer and BioNTech concerning COVID-19 variant-adapted vaccines and related manufacturing technology, culminating in a global resolution announced in August 2025. Under the agreements, CureVac and GSK received a $740 million payment plus single-digit royalties on U.S. COVID-19 vaccine sales going forward. Mark has tried cases as first-chair trial counsel and argued appeals to the Federal Circuit, delivering winning results for life-sciences innovators.

Mark’s success is rooted in a deep scientific background in synthetic organic chemistry and experience prosecuting patent applications. He has represented clients including Spectrum Pharmaceuticals in a series of litigations and at trial, including as first-chair trial counsel in a January 2015 bench trial and subsequent appeal involving Spectrum’s oncology drug Fusilev®. Mark’s training includes an M.S. in chemistry, cutting-edge research at The Scripps Research Institute, and applied work at Abbott Laboratories.

The University of Chicago Law School (J.D.) University of California, San Diego (M.S.) Chemistry State University of New York, Buffalo (B.S.) Biochemistry